Antibody Ingredients TRIZ Cases

A tetravalent bispecific antibody merges anti-EGFR and anti-CD3 binding domains into a single polypeptide chain to recruit immune cells directly.

Specific amino acid mutations in the CD38 antibody Fc region enhance cytotoxicity and enzyme inhibition to overcome limited therapeutic efficacy.

Engineered antibody sequences achieve high binding affinity to BCMA, addressing inadequate treatment efficacy for multiple myeloma.

DeltaRex-G retrovector targets proliferative immune cells to reduce cytokine release and minimize ARDS severity.

Antigen-binding fragments isolate variable regions to inhibit B7-H3 activity, reducing therapeutic complexity while enhancing immune response against cancer.

Humanized anti-CD81 monoclonal antibodies block CD81-mediated tumor cell motility and regulatory T cell suppression, reducing metastasis.

Engineered pH-dependent anti-PD-L1 Fabs bind strongly to tumor targets while sparing healthy tissue, reducing peripheral toxicity in cancer therapy.

Specific inhibitors target the CLEC14A-MMRN2 interface to resolve antibody complexity issues while reducing tumor neovasculature formation.

PI3K inhibitors deplete T follicular regulatory cells, resolving the trade-off between enhanced anti-tumor immunity and immune-related adverse events.

Trispecific molecules bind cancer antigens and activate T cell receptors, reducing side effects on normal cells.

Arginine and alcohol washing buffer removes host cell proteins during protein A chromatography.

Anti-DKK1 monoclonal antibodies suppress tumor growth and metastasis in liver cancer patients with high serum DKK1 levels.

Asymmetric antigen binding molecules reconstitute functional CD3 domains on tumor surfaces to engage cytotoxic T-cells.

Anti-PD1 antibodies treat mismatch repair deficient rectal cancer by activating immune responses, avoiding surgery and preserving organ function.

Segmented ISVDs penetrate tumors effectively while maintaining high neutralizing activity against c-Met.

Humanized antibodies bind ITGA2 on metastatic cancer cells, delivering cytotoxic payloads to improve long-term survival rates.

Antibodies targeting Bcl-2 heterodimers enable direct detection in solid tumor samples to predict patient sensitivity to cancer treatments.

Removing the Fc region eliminates off-target hematopoietic cell interaction while preserving CCR7 affinity for tumor targeting.

Optimized anti-CD100 antibodies block CD100 signaling pathways, addressing insufficient treatment efficacy for associated diseases.

Fully human antibody drug conjugates target FLT3-expressing leukemia cells with high specificity.

Bispecific antibodies bind B7-H4 and CD3 to recruit immune cells, inhibiting tumor growth in cancers expressing this antigen.

A bispecific antibody binds extracellular domains of ERBB2 and ERBB3 to block receptor heterodimerization.

Neutralizing alpha 2 antiplasmin with specific antibodies enhances plasmin activity for effective clot dissolution without increasing bleeding risks.

Single-domain antibodies cross cell membranes autonomously to inhibit STAT3 and KRAS proliferation, eliminating toxicity from exogenous targeting agents.

A recombinant antibody composition combining multiple distinct anti-EGFR molecules to enhance binding density and therapeutic efficacy.

Trispecific antibodies bind HER2 and blood-brain barrier receptors to enable targeted delivery across the endothelial interface.

Recombinant poxviruses encoding tumor antigens combine with immune checkpoint inhibitors to stimulate anti-tumor immunity.

Antibodies bind DDR2 extracellular domains to reduce Col1a1 and Fn1 mRNA levels in fibrotic tissues.

CS-17 monoclonal antibody binds thyrotropin receptor to suppress ligand-independent constitutive activity.

Conjugating peptide ligands to a biopolymer scaffold enables intracorporeal antibody depletion, avoiding costly extracorporeal immunoapheresis procedures.

Antigen-binding protein constructs with histidine substitutions enable pH-dependent dissociation rates for targeted delivery.

FAP-targeted CD40 agonists localize immune activation to reduce systemic toxicity while enhancing anti-tumor efficacy.

Deleting SUSD2 from CD8+ T cells restores effector functions, overcoming immunosuppressive tumor microenvironments.

A 5T4-targeting superantigen conjugate kills glioblastoma cells by bridging immune T-cells to tumor antigens.

Plant cell production eliminates mammalian heterogeneity to ensure consistent product quality and clinical efficacy.

Specific binding compounds measure galectin-1 concentrations to resolve detection accuracy challenges in immune disorder diagnosis.

Ex vivo modified B cells express homing receptors to target bone metastasis, resolving refractory long-term management challenges.

Antibodies bind the Notch1 membrane proximal region to block signaling and reduce cancer stem cell frequency.

Defined monoclonal antibody CDRs potentiate LH and FSH activity, eliminating anti-eCG immune responses while inducing ovulation.

Histidine residues in CDR domains enable acidic pH-selective binding, reducing on-target off-tumor toxicity while maintaining therapeutic efficacy.

Detecting decreased auto-antibody levels against EGFR provides accurate staging and prognosis for ovarian cancer without invasive surgical procedures.

Combining MEK1/2 and AXL inhibitors prevents proteolytic shedding to overcome cancer resistance mechanisms.

Amide surrogate linkers replace vulnerable amide bonds in antibody-drug conjugates, preventing premature cleavage and systemic side effects during circulation.

Hybridoma-derived monoclonal antibodies bind human PTPRS to isolate plasmacytoid dendritic cells and suppress interferon production in autoimmune therapies.

Optimized antibody variable domains enhance binding affinity to address limited survival in metastatic castration-resistant prostate cancer.

Antibodies targeting O-acetylated GD2 ganglioside avoid peripheral nerve binding, reducing neurotoxicity in cancer therapy.

A spacer separates bispecific binding domains to enhance selectivity and reduce off-target toxicity.

Anti-CCR7 antibodies selectively deplete pathogenic T cells to prevent GVHD while preserving the graft-versus-tumor effect.

Single-domain CLEC12A polypeptides reduce off-tumor toxicity by minimizing interaction with normal myeloid cells.